Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis

British Journal of Clinical Pharmacology

Volumn 83, Issue 3, 2017, Pages 642-652

  Komen, Joris ^a,b   Forslund, Tomas ^a,c   Hjemdahl, Paul ^a   Andersen, Morten ^a   Wettermark, Björn ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UTRECHT UNIVERSITY   (Netherlands)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

drug regulation; drug utilization; health policy

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; DRUG CHOICE; DRUG SAFETY; DRUG UTILIZATION; EUROPEAN; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; REIMBURSEMENT; RETROSPECTIVE STUDY; EPIDEMIOLOGY; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA; SWEDEN; TRENDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG UTILIZATION; GUIDELINES AS TOPIC; HEALTH POLICY; HUMANS; INTERRUPTED TIME SERIES ANALYSIS; SWEDEN;

EID: 85006098453     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13150     Document Type: Article

References (48)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44: D1054–D1068.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867.
3. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360–1420.
4. Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013; 8: e63479.
5. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095–1106.
6. Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol 2013; 26: 103–114.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
9. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
10. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013; 2013: 464–470.
11. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2013; 11: 390–394.
12. Marshall S, Fearon P, Dawson J, Quinn TJ. Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 2013; 13: 29–42.
13. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385–1413.
14. European Medicines Agency. Praxbind: EPAR – product information [online]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003986/WC500197464.pdf (last accessed 4 April 2016).
15. European Medicines Agency. Pradaxa: EPAR – product information [online]. 2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (last accessed 29 February 2016).
16. European Medicines Agency. Eliquis: EPAR – product information [online]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (last accessed 29 February 2016).
17. European Medicines Agency. Xarelto: EPAR – product information [online]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (last accessed 29 February 2016).
18. Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013; 4: 39.
19. TLV. Pradaxa ingår i högkostnadsskyddet [online]. Tandvårds- och läkemedelsförmånsverket. Available at http://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/pradaxa-mot-blodpropp-subventioneras1/ (last accessed 16 March 2016).
20. TLV. Xarelto ingår i högkostnadsskyddet [online]. Tandvårds- och läkemedelsförmånsverket. Available at http://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/xarelto-ingar-i-hogkostnadsskyddet/ (last accessed 16 March 2016).
21. TLV. Eliquis ingår i högkostnadsskyddet [online]. Tandvårds- och läkemedelsförmånsverket. Available at http://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/eliquis-ingar-i-hogkostnadsskyddet/ (last accessed 16 March 2016).
22. Socialstyrelsen. Nationella riktlinjer för hjärtsjukvård [online]. 2015. Available at http://www.socialstyrelsen.se/nationellariktlinjerhjartsjukvard (last accessed 5 April 2016).
23. Stockholm County Council (Healthcare Region). The Wise List 2015. 2015.
24. Lip GYH, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol 2016; 204: 88–94.
25. Thorpe KE. The rise in health care spending and what to do about it. Health Aff (Millwood) 2005; 24: 1436–1445.
26. Grol R, Grimshaw JM. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003; 362: 1225–1230.
27. Sjöqvist F, Bergman U, Dahl M. Drug and therapeutics committees: a Swedish experience. WHO Drug Inf 2002; 16: 205–268.
28. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol 2013; 170: 208–214.
29. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299–309.
30. Box GEP, Jenkins GM. Time Series Analysis: Forecasting and Control. San Francisco CA: Holden-Day, 1976.
31. Durbin J, Watson GS. Testing for serial autocorrelation in least square regression. Biometrika 1950; 37: 409–428.
32. Draper NR, Smith H. Applied Regression Analysis, Third edn, Wiley-Interscience. John Wiley & Sons, Inc., 1998.
33. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, et al. The ‘wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011; 108: 224–233.
34. Alpert JS. The NOACs (novel oral anticoagulants) have landed! Am J Med 2014; 127: 1027–1028.
35. Weitz JI, Semchuk W, Turpie AGG, Fisher WD, Kong C, Ciaccia A, et al. Trends in prescribing oral anticoagulants in Canada, 2008–2014. Clin Ther 2015; 37: 2506–2514. e4.
36. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264–2273.
37. Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open 2013; 1: E115–E119.
38. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med 2015; 128: 1300–1305. e2.
39. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol 2015; 115: 1095–1101.
40. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2015; 115: 31–39.
41. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5: 615–621.
42. Soumerai SB, Avorn J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAMA 1990; 263: 549–556.
43. Mason AR, Drummond MF, Hunter JA, Towse AK, Cooke J. Prescribing incentive schemes: a useful approach? Appl Health Econ Health Policy 2005; 4: 111–117.
44. Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev 2007; 3: CD006731.
45. Wettermark B, Haglund K, Gustafsson LL, Persson PM, Bergman U. A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf 2005; 14: 579–588.
46. Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol 2015; 68: 950–956.
47. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care 2003; 19: 613–623.
48. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim J-L, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.